EUVIMEDEUVIMED entdecken
Crossref

Cardiologist-Delivered Genetic Testing in 482 Patients With Cardiomyopathy: The Infrastructure Needed for Mainstream Testing at Scale

Omid Kiamanesh iD, Susan Christian iD, Robert Miller iD, Kristin Lyons, Jonathan Howlett iD, Lea Harper iD, Lauren Archer iD, Noelle Mahon iD, Julien Marcadier iD, Kim McBride iD

Circulation: Genomic and Precision Medicine · 02.10.2026

DOI: 10.1161/circgen.126.005782 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation: Genomic and Precision Medicine, online erschienen am 02.10.2026. Verfasst von Omid Kiamanesh und 9 weiteren Autor:innen. Beteiligte Einrichtung: Broderick Cardiomyopathy Program, Libin Cardiovascular Institute, University of Calgary, Canada (O.K., R.M., K.L., J.H., L.H., L.A., N.M.). Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Mainstream cardiac genetic testing, in which the treating cardiologist orders and returns multigene panel results without a traditional genetic counseling session, may expand access, but no mainstream program has quantified the operational burden. We quantified high-risk genotypes, variant reclassification, and carrier findings in a mainstream cardiomyopathy testing program to characterize the infrastructure required for safe scale-up. METHODS: We retrospectively analyzed 482 consecutive patients with dilated cardiomyopathy (n=338), nondilated left ventricular cardiomyopathy (n=84), or hypertrophic cardiomyopathy (n=60) who underwent multigene panel testing ordered by cardiologists at the Broderick Cardiomyopathy Program (January 2022 to February 2026). Variant classifications used each laboratory’s most current interpretation. RESULTS: Diagnostic pathogenic/likely pathogenic variants were identified in 95 of 482 patients (yield, 19.7% [95% CI, 16.4%–23.5%]) across 21 genes. Three categories of results required program-level infrastructure: (1) 18 of 95 genotype-positive patients (18.9%) had high-risk genotypes ( DSP , LMNA , FLNC [truncating], RBM20 , DES ) requiring genotype-specific management; (2) 8 of 12 reclassified variants (12/743 total, 1.6%) crossed the pathogenic/likely pathogenic threshold, including 7 variant of uncertain significance-to- pathogenic/likely pathogenic upgrades converting nondiagnostic patients to genotype-positive; and (3) carrier findings comprised 26 of 121 pathogenic/likely pathogenic variants (21.5%), inflating apparent yield to 23.7% if carrier findings were not distinguished from diagnostic results based on gene inheritance pattern. Variants of uncertain significance were reported in 295 patients (61.2%). CONCLUSIONS: These data identify 5 capabilities that support safe mainstream scale-up: high-risk genotype pathways for the 1 in 5 diagnostic patients with a high-risk variant, variant surveillance with recontact capacity for the 1 in 60 patients affected by actionable reclassification, recognition of gene inheritance pattern for the 1 in 19 patients with a carrier finding, a defined referral pathway to medical genetics, and standardized family screening infrastructure for all result categories.

Schlagwörter

Stichwörter der Autor:innen

cardiomyopathy, hypertrophiccounselinggenetic testinggenotypepatients

Autor:innen und Institutionen

  • Broderick Cardiomyopathy Program, Libin Cardiovascular Institute, University of Calgary, Canada (O.K., R.M., K.L., J.H., L.H., L.A., N.M.).
  • Department of Medical Genetics, University of Alberta, Edmonton, Canada (S.C.).
  • Department of Clinical Genetics, Alberta Health Services, Calgary, Canada (J.M., K.M.).

ORCID-Profile: Omid Kiamanesh, Susan Christian, Robert Miller, Jonathan Howlett, Lea Harper, Lauren Archer, Noelle Mahon, Julien Marcadier, Kim McBride

Zitieren

APA

Kiamanesh, O., Christian, S., Miller, R., Lyons, K., Howlett, J., Harper, L., Archer, L., Mahon, N., Marcadier, J., & McBride, K. (2026). Cardiologist-Delivered Genetic Testing in 482 Patients With Cardiomyopathy: The Infrastructure Needed for Mainstream Testing at Scale. Circulation: Genomic and Precision Medicine. https://doi.org/10.1161/circgen.126.005782

Vancouver

Kiamanesh O, Christian S, Miller R, Lyons K, Howlett J, Harper L, et al. Cardiologist-Delivered Genetic Testing in 482 Patients With Cardiomyopathy: The Infrastructure Needed for Mainstream Testing at Scale. Circulation: Genomic and Precision Medicine. 2026. doi:10.1161/circgen.126.005782

BibTeX
@article{Kiamanesh2026,
  author = {Kiamanesh, Omid and Christian, Susan and Miller, Robert and Lyons, Kristin and Howlett, Jonathan and Harper, Lea and Archer, Lauren and Mahon, Noelle and Marcadier, Julien and McBride, Kim},
  title = {Cardiologist-Delivered Genetic Testing in 482 Patients With Cardiomyopathy: The Infrastructure Needed for Mainstream Testing at Scale},
  journal = {Circulation: Genomic and Precision Medicine},
  year = {2026},
  doi = {10.1161/circgen.126.005782}
}
Kostenlos starten →